Physician
Oncology
Dr. Lawrence P. Leichman, MD
|
|
Give Review
Lawrence Leichman practices Oncology. He attended Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Lawrence P. Leichman is also published. He has 90 publications published. The lastest publication: "Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.' Lawrence Leichman is registered with Medicare.
Publications
- Comparison of anal Cancer outcomes in public and private hospital patients treated at a single radiation oncology center.
- A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metast...
- Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal Cancer.
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal Cancer.
- NO147: The Giving Tree.
- Safety and pharmacokinetics of high-dose gefitinib in patients with solid Tumors: results of a phase I study.
- S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophag...
- Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally-advanced or metastatic solid Tumors.
- Squamous cell Cancer of the esophagus: the forgotten one.
- Cetuximab as second-line therapy in patients with metastatic esophageal adenoCarcinoma: a phase II Southwest Oncology Group Study (S0415).
- On target? Off target? Why we really do not know.
- Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin Lymphoma.
- The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal Cancer.
- Paclitaxel given by a weekly 1-h infusion in advanced esophageal Cancer.
- Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal Cancer in patients receiving oxaliplatin, 5-flou...
- Neoadjuvant chemotherapy for disseminated colorectal Cancer: changing the paradigm.
- Definitive and neoadjuvant therapies for Esophageal and gastroEsophageal junction tumors: a look back and toward the future.
- Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic Cancer.
- Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal Cancer: dose-volume histogram analysis.
- Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal Cancer.
- Diagnostic dilemmas in oncology: case 3. Pericardial effusion after Esophageal radiation.
- Therapy of disseminated colorectal Cancer: the emerging role of intratumoral molecular biology.
- Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenoCarcinoma of the stomach.
- ColoRectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
- Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid Tumors.
- High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in coloRectal tumors is associated with nonresponse to 5-...
- p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal Cancer: an analysis of response and survival.
- p53 and thymidylate synthase expression in untreated stage II colon Cancer: associations with recurrence, survival, and site.
- ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric Cancer patients receiving combination cisplatin and fluor...
- Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal Cancer response and resistance to protracted-infusion fluorouracil an...
- High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell Carcinoma of the esophagus but not in adenoCarcinoma of the esophagus or stomach.
- Systemic chemotherapy for gastric Carcinoma followed by postoperative intraperitoneal therapy: a final report.
- Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal Cancer: an intergroup study.
- Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.
- Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
- A pilot trial of continuous infusion 5-fluorouracil with levamisole for adjuvant therapy of colon Cancer.
- Thymidylate synthase mRNA level in adenoCarcinoma of the stomach: a predictor for primary tumor response and overall survival.
- Identification of mutations by RNA conformational polymorphism "bar code" Analysis.
- Quantitation of intratumoral thymidylate synthase expression predicts for resistance to proTracted infusion of 5-fluorouracil and weekly leucovorin in disseminated col...
- Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human coloRectal and gastric tumors.
- A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal Cancer.
- Intraperitoneal 5-fluoro-2''-deoxyuridine (FUDR) and (S)-leucovorin for Disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.
- Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report.
- Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.
- Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal Cancer.
- Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric Cancer: a University of Southern California pilot program.
- Effects of preoperative chemotherapy on gastric adenoCarcinomas. A morphologic study of 25 cases.
- Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with Cancer of the esophagus.
- High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric Cancers.
- Quantitation of thymidylate synthase, dihydrofolate reDuctase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.
- Experience with cisplatin in treatment regimens for esophageal Cancer.
- Cisplatin therapy for adenoCarcinoma of the stomach.
- Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2''-deoxyuridine.
- Anal carcinoma.
- Hyperfractionated radiation and chemotherapy for unresectable localized adenoCarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
- Biological modification of proTracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal ...
- Cancer of the esophagus: the Wayne State University experience.
- The role of chemotherapy in the treatment of squamous cell Tumors of the esophagus.
- Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience.
- Acute Leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
- Preoperative radiation and chemotherapy for localized squamous cell Carcinoma of the esophagus: a RTOG Study.
- Primary adenoCarcinoma of the esophagus.
- Combined therapies for squamous-cell Carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037).
- Nonoperative therapy for squamous-cell Cancer of the esophagus.
- High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhemat...
- Carboplatin: a new platinum Analog in the treatment of epidermoid carcinoma of the esophagus.
- Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
- Chemotherapy for advanced epidermoid Carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study.
- Combined preoperative chemotherapy and radiation therapy for Cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncolo...
- Preoperative chemotherapy and radiation therapy for patients with Cancer of the esophagus: a potentially curative approach.
- Cisplatin. An active drug in the treatment of disseminated gastric Cancer.
- Celestin tube use: radiographic manifestations of associated complications.
- Management of malignant bronchoEsophageal fistulas.
- Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
- Phase II trial of m-AMSA in gallBladder and cholangiocarcinoma: a Southwest Oncology Group Study.
- Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the Anal cAnal.
- Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenoCarcinoma: a Southwest Oncology G...
- Methyl-GAG in advanced colon Cancer: a phase II trial of the Southwest Oncology Group.
- Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenoCarcinoma of the pancreas: a Southwest Oncology Group Study.
- Phase II study of high-dose intermittent cycloleucine in coloRectal malignancies.
- Eradication and palliation of squamous cell Carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy.
- Total parenteral nutrition in Cancer patients.
- Complete eradication of squamous cell Carcinoma of the esophagus with combined chemotherapy and radiotherapy.
- Cis-diamminedichloride platinum(II), an effective agent in the treatment of epidermoid Carcinoma of the esophagus. A preliminary report of an ongoing Southwest Oncolog...
- Mitomycin C and bleomycin in the treatment of far-advanced cervical Cancer: a Southwest Oncology Group pilot study.
- The current status of neoadjuvant therapy for esophageal Cancer.
- Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials.
- Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
- A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic Cancer: an Academic Oncology...
Schools
Wayne State University School Of Medicine
Detroit Genl Hospital
Wayne
Procedures Preformed
- Cancer Counseling
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Wayne State University School of Medicine
Hospital
-
NYU Langone Medical Center
Drug Facts
| NPI NUMBER | 1891792305 | |
| NPPES Provider LastName | LEICHMAN | |
| NPPES Provider FirstName | LAWRENCE | |
| NPPES Provider ZIPCode | 922624885 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 95.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891792305 |
| Last Name Of The Provider | LEICHMAN |
| First Name Of The Provider | LAWRENCE |
| View All |
Similar Doctors
|
Dr. Mehmet F. Hepgur, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Enrico C. Sobong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark M. Coleman, MD |